Alnylam to present additional data for patisiran in patients with the cardiomyopathy of attr amyloidosis, including 24-month results from the apollo-b phase 3 study, at the heart failure society of america annual scientific meeting 2023

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the company will present new results for patisiran, an investigational rnai therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (attr) amyloidosis, at the heart failure society of america (hfsa) annual scientific meeting (asm) 2023, october 6-9, 2023. data from an interim analysis of the ongoing open-label extension.
ALNY Ratings Summary
ALNY Quant Ranking